Changeflow GovPing Pharma & Drug Safety SGLT-2 Inhibitor Pharmaceutical Composition for...
Routine Notice Added Final

SGLT-2 Inhibitor Pharmaceutical Composition for Diabetes Treatment

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO published patent application US20260097058A1 for a pharmaceutical composition containing SGLT-2 inhibitors for treating diabetes mellitus, impaired glucose tolerance, hyperglycemia, and metabolic disorders. Inventors include Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, and Rolf Grempler. The application was filed on December 11, 2025.

What changed

The USPTO published a patent application for a pharmaceutical composition using SGLT-2 inhibitors to treat diabetes mellitus (types 1 and 2), impaired glucose tolerance, hyperglycemia, and related metabolic disorders. The application covers methods for treatment and prevention using the disclosed composition.

Affected parties including pharmaceutical companies, drug developers, and healthcare providers should monitor this application for potential patent claims that may affect future diabetes treatments using SGLT-2 inhibitors. The published application establishes priority dates and defines the scope of intellectual property protection sought for the disclosed invention.

What to do next

  1. Monitor application status for patent issuance

Archived snapshot

Apr 12, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF

Application US20260097058A1 Kind: A1 Apr 09, 2026

Inventors

Peter EICKELMANN, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, Rolf Grempler

Abstract

The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

CPC Classifications

A61K 31/7034 A61K 31/7048

Filing Date

2025-12-11

Application No.

19415956

View original document →

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260097058A1
Docket
19415956

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent filing Drug development IP strategy
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!